Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab and Tremelimumab with Chemotherapy in ICC
NCT04989218Phase 2Terminated
- Sponsor
- University of Alabama at Birmingham
- Start
- Jan 2023
- Primary completion
- Mar 2024
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
A Phase 2 trial of durvalumab, tremelimumab in intrahepatic cholangiocarcinoma (ICC), sponsored by University of Alabama at Birmingham. Started Jan 2023; status: terminated.
02
Drugs
durvalumabtremelimumab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT04989218.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04989218.